Cor Vasa 2019, 61(6):606-610 | DOI: 10.33678/cor.2019.069

(In what extent we reached the standards of antiplatelet therapy in secondary prevention of myocardial infarction)

Petr König, Otto Mayer jr.
II. interní klinika, Lékařská fakulta Plzeň, Univerzita Karlova v Praze a Fakultní nemocnice Plzeň, Plzeň

Appropriate pharmacologic control of platelet aggregation represents pivotal treatment target in acute phase of myocardial infarction and in secondary prevention. It is evident for several years, that clopidogrel-based dual antiplatelet treatment does not have a suitable efficacy in several patients. Because of more favorable pharmacodynamics properties, ticagrelor represents more appropriate solution, but its extensive use was opposed by an economical reason. Moreover, recent findings show that patients with impaired glomerular filtration benefit from ticagrelor based treatment in a larger extent than those with maintained normal renal functions. We analyzed the prescription data of antiplatelets in the Czech Republic and approximate, how many patients after myocardial infarction showed impaired renal function.

Keywords: Antiplatelets, Prescription rate, Secondary prevention, Ticagrelor

Received: August 22, 2019; Accepted: October 14, 2019; Published: December 15, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
König P, Mayer O. (In what extent we reached the standards of antiplatelet therapy in secondary prevention of myocardial infarction). Cor Vasa. 2019;61(6):606-610. doi: 10.33678/cor.2019.069.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502. Go to original source... Go to PubMed...
    2. Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high- -dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011;305:1097-1105. Go to original source... Go to PubMed...
    3. Mehta SR, Bassand JP, Chrolavicius S, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010;363:930-942. Go to original source... Go to PubMed...
    4. Parodi G, Marcucci R, Valenti R, et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA 2011;306:1215-1223. Go to original source... Go to PubMed...
    5. Mega JL, Hochholzer W, Frelinger AL, 3rd, et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA 2011;306:2221-2228. Go to original source... Go to PubMed...
    6. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-2015. Go to original source... Go to PubMed...
    7. Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 2010;376:1320-1328. Go to original source... Go to PubMed...
    8. Shah R, Hwang I, Nayyar M, et al. Relative efficacy and safety of oral P2Y12 inhibitors in acute coronary syndrome: An Updated Network Meta-Analysis of Randomized Trials In. J Am Coll Cardiol 2016;41. Go to original source...
    9. James S, Budaj A, Aylward P, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 2010;122:1056-1067. Go to original source... Go to PubMed...
    10. Katsanos K, Spiliopoulos S, Saha P, et al. Comparative Efficacy and Safety of Different Antiplatelet Agents for Prevention of Major Cardiovascular Events and Leg Amputations in Patients with Peripheral Arterial Disease: A Systematic Review and Network Meta-Analysis. PLoS One 2015;10:e0135692. Go to original source... Go to PubMed...
    11. Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32:2999-3054. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes